Immunovant (NASDAQ: IMVT) saw its stock price surge 35.3% to close at $35.56 on Wednesday, following the release of encouraging 16-week data for its experimental rheumatoid arthritis drug, IMVT-1402. The strong performance made the biotech one of the top gainers in the U.S. healthcare sector for the day. Roivant Sciences (NASDAQ: ROIV), Immunovant's majority owner, also benefited, closing approximately 14.9% higher at $32.41.
The rally reflects investor optimism that IMVT-1402, now Immunovant's primary asset, could expand beyond its lead autoimmune indications. The broader market also saw gains, with the Nasdaq rising 1.55% and the S&P 500 adding 1.08%, according to data from Investing.com.
Clinical Data Highlights
Immunovant reported that IMVT-1402 achieved ACR20, ACR50, and ACR70 response rates of 72.7%, 54.5%, and 35.8%, respectively, after 16 weeks in an open-label portion of a study targeting difficult-to-treat rheumatoid arthritis. ACR20 is a standard measure indicating at least a 20% improvement in tender and swollen joint counts, along with other clinical measures.
The trial enrolled 170 patients, with 165 evaluable participants receiving a weekly 600-mg subcutaneous dose. Notably, 86.7% of these patients had previously failed two advanced therapies, making the results particularly relevant for a hard-to-treat population with limited options.
In a subset of patients who had failed both a JAK inhibitor and an anti-TNF drug—two major classes of rheumatoid arthritis treatments—the drug showed ACR20, ACR50, and ACR70 response rates of 72.0%, 53.3%, and 37.4%. Immunovant noted no new drug-related safety signals and used independent joint assessors blinded to treatment status to minimize bias.
Wall Street Reaction and Analyst Commentary
Leerink Partners analyst David Risinger described the data as “highly compelling,” suggesting that IMVT-1402 has the “potential to become a blockbuster,” a term for drugs with annual sales exceeding $1 billion. His assessment helped frame the readout as a significant milestone beyond a routine clinical update.
Roivant CEO Matt Gline highlighted the “exciting potential for a new, differentiated mechanism” in rheumatoid arthritis patients who have failed multiple prior therapies. Roivant also noted that further updates from the rheumatoid arthritis trial, along with top-line data from a cutaneous lupus erythematosus study, are expected in the second half of 2026.
Mechanism of Action and Competitive Landscape
IMVT-1402 targets the neonatal Fc receptor (FcRn), a protein that helps maintain IgG antibody levels in the body. By blocking FcRn, the drug aims to accelerate the breakdown of harmful IgG autoantibodies that drive autoimmune diseases. Competitors in the FcRn space include argenx's Vyvgart, UCB's Rystiggo, and Johnson & Johnson's Imaavy, though these are primarily approved for myasthenia gravis rather than rheumatoid arthritis.
Financial Context and Cash Position
The positive clinical news overshadowed a weaker financial report. Immunovant posted a fiscal fourth-quarter net loss of $147.9 million, or $0.73 per share, compared to consensus estimates of a $0.60 loss per share from MarketBeat. Research and development spending increased as the company advanced IMVT-1402 trials and wound down work on batoclimab.
However, the company ended March with approximately $902.1 million in cash and cash equivalents, sufficient to fund announced indications through the potential commercial launch of IMVT-1402 in Graves' disease. Immunovant expects top-line data from potentially registrational trials in Graves' disease and myasthenia gravis in 2027.
Risks and Outlook
Despite the enthusiasm, risks remain. The rheumatoid arthritis data came from an open-label period, not a fully blinded, placebo-controlled efficacy readout. The ongoing randomized withdrawal portion could yield different results. Roivant also cautioned that product-candidate potential, trial timing, approvals, and commercial outcomes are forward-looking and subject to risks, including the possibility that later trials may not match early results.
For now, investors view the readout as a reset for Immunovant following a Phase 3 miss for batoclimab in thyroid eye disease in April, which led the company to discontinue batoclimab and focus entirely on IMVT-1402. The next challenge will be converting Wednesday's strong early signal into a clearer regulatory path, without letting the stock's new premium outpace the underlying data.
